{
  "first_published_at": "2008-05-01", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON085086", 
  "title": "Monitoring the safety of antiretroviral drugs", 
  "tags": "{\"parsed_therapeutic\": [\"infectious-disease\"], \"Audience:\": [\"Primary care\", \"Secondary care\"], \"Therapeutic area:\": [\"Infectious disease\"]}", 
  "_document_number": 290, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/Yellowcard_icon.png", 
  "therapeutic_area": [
    "infectious-disease"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Monitoring the safety of antiretroviral drugs</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: May 2008</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!--The first antiretroviral drug, zidovudine, became available more than 20 years ago, and since then there have been substantial advances in the treatment options available to patients with HIV and in their prognosis. The advent of new drug classes and in combination therapy has not only led to important benefits for patients, but also to the need for ongoing monitoring and management of the risks associated with treatment.-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>The first antiretroviral drug, zidovudine, became available more than 20 years ago, and since then there have been substantial advances in the treatment options available to patients with HIV and in their prognosis. The advent of new drug classes and in combination therapy has not only led to important benefits for patients, but also to the need for ongoing monitoring and management of the risks associated with treatment.</p><p>The clinical need for new or improved treatments for HIV is usually perceived as urgent and most new treatments are made available for use as quickly as possible. Therefore, knowledge of a drug&rsquo;s safety is incomplete when it first becomes available and it is monitored closely after marketing.</p><p>Recent examples of new treatments or new formulations or combinations, of treatments, for HIV include:<br></p><ul>\r\n\t\t\t<li>Maraviroc (Celsentri &#9660;): the first CCR5 inhibitor</li>\r\n\t\t\t<li>Raltegravir (Isentress &#9660;): the first integrase inhibitor</li>\r\n\t\t\t<li>Duranavir (Prezista &#9660;): a new protease inhibitor for highly pretreated patients</li>\r\n\t\t\t<li>Atripla: a new combination tablet of efavirenz, tenofovir, and emtricitabine</li></ul><p>To help improve knowledge about the safety of a new medicine, a company that holds a Marketing Authorisation for it now produces a risk-management plan. A summary of the plan can be found in the <a href=\"http://www.ema.europa.eu/ema/index.jsp?curl=/pages/medicines/landing/epar_search.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d124\" target=\"_blank\">European Public Assessment Report</a> of the medicine.</p><p>Of course, safety issues are not associated with newer drugs only. As a consequence of the short-term nature (ie, actual treatment periods) of clinical trials, the long-term safety profile of all antiretrovirals is continually changing.</p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>Recent examples of safety issues associated with older antiretrovirals include:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>Abacavir and didanosine: increased risk of myocardial infarction (findings from the D:A:D study: see article in <a href=\"ssLINK/CON085146\" target=\"_blank\">Drug Safety Update, May 2008</a>)&nbsp;and <a href=\"http://www.chip.dk/portals/0/files/DAD%20Position%20statement%20CROI%202008%20FINAL%202.pdf\" target=\"_blank\">position statement from D:A:D steering committee</a>)</li>\r\n\t\t\t\t<li>Norvir (ritonavir): <a href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000127/human_med_000932.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d124\" target=\"_blank\">new drug interactions</a> (eg, with buprenorphine)</li>\r\n\t\t\t\t<li>Crixivan (indinavir): <a href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000128/human_med_000729.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d124\" target=\"_blank\">renal failure</a></li>\r\n\t\t\t\t<li>Sustiva (efavirenz): <a href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000249/human_med_001068.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d124\" target=\"_blank\">gynaecomastia</a></li>\r\n\t\t\t\t<li>Viread (tenofovir): <a href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000249/human_med_001068.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d124\" target=\"_blank\">risk of hepatitis B reactivation</a> after withdrawal</li>\r\n\t\t\t\t<li>Telzir (fosamprenavir): <a href=\"risk%20of%20hepatitis%20B%20reactivation\" target=\"_blank\">angioedema</a></li>\r\n\t\t\t\t<li>All antiretrovirals: osteonecrosis (see <a href=\"http://www.bnf.org/\" target=\"_blank\">British National Formulary</a> 54th edn, September 2007, section 5.3.1 HIV infection, p 325)</li>\r\n\t\t\t\t<li>Effect of proton pump inhibitors on protease inhibitor blood levels (for <a href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000494/human_med_001035.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d124\" target=\"_blank\">Reyataz</a> and <a href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000494/human_med_001035.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d124\" target=\"_blank\">Kaletra</a>)</li>\r\n\t\t\t\t<li>Kaletra (lopinavir with ritonavir): <a href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON2032268\" target=\"_blank\">overdosing of neonates</a></li>\r\n\t\t\t</ul></div><h2>Reporting of suspected adverse drug reactions</h2><p>The <a href=\"http://www.yellowcard.gov.uk/\" target=\"_blank\">Yellow Card Scheme</a> is an important way of detecting emerging safety issues for medicines. We use reports of suspected adverse effects of drugs (or interactions with other drugs, herbal products, or food supplements) from healthcare professionals and patients or carers to determine whether information for a medicine accurately reflects its safety profile.</p><p>For all Yellow Cards we receive, it is important to note that patient and reporter confidentiality is maintained. Specific guidance on the reporting of suspected adverse reactions to antiretrovirals can be found on our website. In addition to the basic information included on a Yellow Card report, it is very helpful for our assessment of these reports to know the following:<br></p><ul>\r\n\t\t\t<li>CD4 count</li>\r\n\t\t\t<li>Lowest ever CD4 count</li>\r\n\t\t\t<li>CD4 count at start of treatment</li>\r\n\t\t\t<li>HIV viral load</li>\r\n\t\t\t<li>Relevant test results (including baseline values)</li>\r\n\t\t\t<li>Drug-resistance profile</li>\r\n\t\t\t<li>Previous illness</li>\r\n\t\t\t<li>Previous sideeffects</li></ul><p>For more information see the MHRA webpage: <a href=\"http://www.mhra.gov.uk/Safetyinformation/Generalsafetyinformationandadvice/Product-specificinformationandadvice/AntiretroviraldrugsforHIV/index.htm\" target=\"_blank\">Monitoring the safety of antiretroviral drugs</a></p><p>&nbsp;</p><p><em>Article citation: Drug Safety Update May 2008; Vol 1, Issue 10: 7</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>The first antiretroviral drug, zidovudine, became available more than 20 years ago, and since then there have been substantial advances in the treatment options available to patients with HIV and in their prognosis. The advent of new drug classes and in combination therapy has not only led to important benefits for patients, but also to the need for ongoing monitoring and management of the risks associated with treatment.</p><p>The clinical need for new or improved treatments for HIV is usually perceived as urgent and most new treatments are made available for use as quickly as possible. Therefore, knowledge of a drug&#8217;s safety is incomplete when it first becomes available and it is monitored closely after marketing.</p><p>Recent examples of new treatments or new formulations or combinations, of treatments, for HIV include:<br></p><ul>\r\n\t\t\t<li>Maraviroc (Celsentri &#9660;): the first CCR5 inhibitor</li>\r\n\t\t\t<li>Raltegravir (Isentress &#9660;): the first integrase inhibitor</li>\r\n\t\t\t<li>Duranavir (Prezista &#9660;): a new protease inhibitor for highly pretreated patients</li>\r\n\t\t\t<li>Atripla: a new combination tablet of efavirenz, tenofovir, and emtricitabine</li></ul><p>To help improve knowledge about the safety of a new medicine, a company that holds a Marketing Authorisation for it now produces a risk-management plan. A summary of the plan can be found in the <a href=\"http://www.ema.europa.eu/ema/index.jsp?curl=/pages/medicines/landing/epar_search.jsp&amp;murl=menus/medicines/medicines.jsp&amp;mid=WC0b01ac058001d124\" target=\"_blank\">European Public Assessment Report</a> of the medicine.</p><p>Of course, safety issues are not associated with newer drugs only. As a consequence of the short-term nature (ie, actual treatment periods) of clinical trials, the long-term safety profile of all antiretrovirals is continually changing.</p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>Recent examples of safety issues associated with older antiretrovirals include:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>Abacavir and didanosine: increased risk of myocardial infarction (findings from the D:A:D study: see article in <a href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/ssLINK/CON085146\" target=\"_blank\">Drug Safety Update, May 2008</a>)&#160;and <a href=\"http://www.chip.dk/portals/0/files/DAD%20Position%20statement%20CROI%202008%20FINAL%202.pdf\" target=\"_blank\">position statement from D:A:D steering committee</a>)</li>\r\n\t\t\t\t<li>Norvir (ritonavir): <a href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000127/human_med_000932.jsp&amp;murl=menus/medicines/medicines.jsp&amp;mid=WC0b01ac058001d124\" target=\"_blank\">new drug interactions</a> (eg, with buprenorphine)</li>\r\n\t\t\t\t<li>Crixivan (indinavir): <a href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000128/human_med_000729.jsp&amp;murl=menus/medicines/medicines.jsp&amp;mid=WC0b01ac058001d124\" target=\"_blank\">renal failure</a></li>\r\n\t\t\t\t<li>Sustiva (efavirenz): <a href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000249/human_med_001068.jsp&amp;murl=menus/medicines/medicines.jsp&amp;mid=WC0b01ac058001d124\" target=\"_blank\">gynaecomastia</a></li>\r\n\t\t\t\t<li>Viread (tenofovir): <a href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000249/human_med_001068.jsp&amp;murl=menus/medicines/medicines.jsp&amp;mid=WC0b01ac058001d124\" target=\"_blank\">risk of hepatitis B reactivation</a> after withdrawal</li>\r\n\t\t\t\t<li>Telzir (fosamprenavir): <a href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/risk%20of%20hepatitis%20B%20reactivation\" target=\"_blank\">angioedema</a></li>\r\n\t\t\t\t<li>All antiretrovirals: osteonecrosis (see <a href=\"http://www.bnf.org/\" target=\"_blank\">British National Formulary</a> 54th edn, September 2007, section 5.3.1 HIV infection, p 325)</li>\r\n\t\t\t\t<li>Effect of proton pump inhibitors on protease inhibitor blood levels (for <a href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000494/human_med_001035.jsp&amp;murl=menus/medicines/medicines.jsp&amp;mid=WC0b01ac058001d124\" target=\"_blank\">Reyataz</a> and <a href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000494/human_med_001035.jsp&amp;murl=menus/medicines/medicines.jsp&amp;mid=WC0b01ac058001d124\" target=\"_blank\">Kaletra</a>)</li>\r\n\t\t\t\t<li>Kaletra (lopinavir with ritonavir): <a href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON2032268\" target=\"_blank\">overdosing of neonates</a></li>\r\n\t\t\t</ul></div><h2>Reporting of suspected adverse drug reactions</h2><p>The <a href=\"http://www.yellowcard.gov.uk/\" target=\"_blank\">Yellow Card Scheme</a> is an important way of detecting emerging safety issues for medicines. We use reports of suspected adverse effects of drugs (or interactions with other drugs, herbal products, or food supplements) from healthcare professionals and patients or carers to determine whether information for a medicine accurately reflects its safety profile.</p><p>For all Yellow Cards we receive, it is important to note that patient and reporter confidentiality is maintained. Specific guidance on the reporting of suspected adverse reactions to antiretrovirals can be found on our website. In addition to the basic information included on a Yellow Card report, it is very helpful for our assessment of these reports to know the following:<br></p><ul>\r\n\t\t\t<li>CD4 count</li>\r\n\t\t\t<li>Lowest ever CD4 count</li>\r\n\t\t\t<li>CD4 count at start of treatment</li>\r\n\t\t\t<li>HIV viral load</li>\r\n\t\t\t<li>Relevant test results (including baseline values)</li>\r\n\t\t\t<li>Drug-resistance profile</li>\r\n\t\t\t<li>Previous illness</li>\r\n\t\t\t<li>Previous sideeffects</li></ul><p>For more information see the MHRA webpage: <a href=\"http://www.mhra.gov.uk/Safetyinformation/Generalsafetyinformationandadvice/Product-specificinformationandadvice/AntiretroviraldrugsforHIV/index.htm\" target=\"_blank\">Monitoring the safety of antiretroviral drugs</a></p><p>&#160;</p><p><em>Article citation: Drug Safety Update May 2008; Vol 1, Issue 10: 7</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2008-05-01", 
  "date_last_modified": "2010-09-17", 
  "_assets": [], 
  "_item_id": 290, 
  "summary": "", 
  "body": "Article date: May 2008\n\nThe first antiretroviral drug, zidovudine, became available more than 20 years ago, and since then there have been substantial advances in the treatment options available to patients with HIV and in their prognosis. The advent of new drug classes and in combination therapy has not only led to important benefits for patients, but also to the need for ongoing monitoring and management of the risks associated with treatment.\n\nThe clinical need for new or improved treatments for HIV is usually perceived as urgent and most new treatments are made available for use as quickly as possible. Therefore, knowledge of a drug’s safety is incomplete when it first becomes available and it is monitored closely after marketing.\n\nRecent examples of new treatments or new formulations or combinations, of treatments, for HIV include:  \n  \n  \n  * Maraviroc (Celsentri ▼): the first CCR5 inhibitor  \n  * Raltegravir (Isentress ▼): the first integrase inhibitor  \n  * Duranavir (Prezista ▼): a new protease inhibitor for highly pretreated patients  \n  * Atripla: a new combination tablet of efavirenz, tenofovir, and emtricitabine  \n  \nTo help improve knowledge about the safety of a new medicine, a company that holds a Marketing Authorisation for it now produces a risk-management plan. A summary of the plan can be found in the [European Public Assessment Report](http://www.ema.europa.eu/ema/index.jsp?curl=/pages/medicines/landing/epar_search.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d124) of the medicine.\n\nOf course, safety issues are not associated with newer drugs only. As a consequence of the short-term nature (ie, actual treatment periods) of clinical trials, the long-term safety profile of all antiretrovirals is continually changing.\n\nRecent examples of safety issues associated with older antiretrovirals include:  \n  \n  * Abacavir and didanosine: increased risk of myocardial infarction (findings from the D:A:D study: see article in [Drug Safety Update, May 2008](http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/ssLINK/CON085146)) and [position statement from D:A:D steering committee](http://www.chip.dk/portals/0/files/DAD%20Position%20statement%20CROI%202008%20FINAL%202.pdf))  \n  * Norvir (ritonavir): [new drug interactions](http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000127/human_med_000932.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d124) (eg, with buprenorphine)  \n  * Crixivan (indinavir): [renal failure](http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000128/human_med_000729.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d124)  \n  * Sustiva (efavirenz): [gynaecomastia](http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000249/human_med_001068.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d124)  \n  * Viread (tenofovir): [risk of hepatitis B reactivation](http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000249/human_med_001068.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d124) after withdrawal  \n  * Telzir (fosamprenavir): [angioedema](http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/risk%20of%20hepatitis%20B%20reactivation)  \n  * All antiretrovirals: osteonecrosis (see [British National Formulary](http://www.bnf.org/) 54th edn, September 2007, section 5.3.1 HIV infection, p 325)  \n  * Effect of proton pump inhibitors on protease inhibitor blood levels (for [Reyataz](http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000494/human_med_001035.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d124) and [Kaletra](http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000494/human_med_001035.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d124))  \n  * Kaletra (lopinavir with ritonavir): [overdosing of neonates](http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON2032268)  \n  \n## Reporting of suspected adverse drug reactions\n\nThe [Yellow Card Scheme](http://www.yellowcard.gov.uk/) is an important way of detecting emerging safety issues for medicines. We use reports of suspected adverse effects of drugs (or interactions with other drugs, herbal products, or food supplements) from healthcare professionals and patients or carers to determine whether information for a medicine accurately reflects its safety profile.\n\nFor all Yellow Cards we receive, it is important to note that patient and reporter confidentiality is maintained. Specific guidance on the reporting of suspected adverse reactions to antiretrovirals can be found on our website. In addition to the basic information included on a Yellow Card report, it is very helpful for our assessment of these reports to know the following:  \n  \n  \n  * CD4 count  \n  * Lowest ever CD4 count  \n  * CD4 count at start of treatment  \n  * HIV viral load  \n  * Relevant test results (including baseline values)  \n  * Drug-resistance profile  \n  * Previous illness  \n  * Previous sideeffects  \n  \nFor more information see the MHRA webpage: [Monitoring the safety of antiretroviral drugs](http://www.mhra.gov.uk/Safetyinformation/Generalsafetyinformationandadvice/Product-specificinformationandadvice/AntiretroviraldrugsforHIV/index.htm)\n\n \n\nArticle citation: Drug Safety Update May 2008; Vol 1, Issue 10: 7\n"
}